Results 261 to 270 of about 82,032 (316)
Some of the next articles are maybe not open access.

Hemophilia A/B

Hematology/Oncology Clinics of North America, 2022
Adeno-associated virus (AAV)-mediated gene transfer has successfully raised, and in some cases transiently normalized, FVIII or FIX activity levels in adults with severe hemophilia. Raising FVIII/IX levels, particularly greater than ∼15 IU/dL (mild deficiency), corresponds to a marked decrease in spontaneous and provoked bleeding, dramatic reduction in
openaire   +2 more sources

Hemophilia A

Hematology/Oncology Clinics of North America, 1992
Over the past few years considerable progress has been made in elucidating the molecular genetics of hemophilia A, in carrier detection and prenatal diagnosis, and in the production of safer clotting factor concentrates. Recombinant FVIII, shown to be safe and effective in ongoing prelicensure clinical trials that began in the spring of 1987, should ...
J M, Lusher, I, Warrier
openaire   +2 more sources

Acquired Hemophilia A

Hematology/Oncology Clinics of North America, 2021
Acquired hemophilia A is a potentially severe bleeding disorder caused by antibodies against the patient's own factor VIII. Acquired hemophilia A is rare. It is most commonly diagnosed in older individuals; about one-half of cases of acquired hemophilia are associated with underlying conditions, including autoimmune disease, cancer, and pregnancy.
openaire   +2 more sources

Blood Coagulation in Hemophilia A and Hemophilia C

Blood, 1998
Tissue factor (TF)-induced coagulation was compared in contact pathway suppressed human blood from normal, factor VIII-deficient, and factor XI-deficient donors. The progress of the reaction was analyzed in quenched samples by immunoassay and immunoblotting for fibrinopeptide A (FPA), thrombin-antithrombin (TAT), factor V activation, and osteonectin ...
Cawthern, K. M.   +5 more
openaire   +3 more sources

Acquired hemophilia A

2011
Acquired hemophilia A is a rare but often life-threatening hemorrhagic disorder characterized by an autoantibody directed against coagulation factor VIII. Fifty per cent of cases are idiopathic whereas the remaining 50% are associated with pregnancy, autoimmune conditions, malignancies and drugs.
Franchini M, LIPPI, Giuseppe
openaire   +2 more sources

A Challenge for Hemophilia Treatment: Hemophilia and Cancer

Journal of Pediatric Hematology/Oncology, 2020
Background: The risk of developing cancer increases with age and also adverse environmental conditions. The same holds true in the aging people with hemophilia (PwH). Furthermore, cancer is an important challenge for physicians working in multidisciplinary hemophilia care centers. Aim:
Basak, Koc, Bulent, Zulfikar
openaire   +2 more sources

Home - About - Disclaimer - Privacy